Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88

Glycobiology

Volumn 20, Issue 2, 2009, Pages 175-186

  Hossain, Md Motarab ^b   Hosono Fukao, Tomomi ^b   Tang, Renhong ^c   Sugaya, Noriko ^d   van Kuppevelt, Toin H ^e   Jenniskens, Guido J ^a,e   Kimata, Koji ^d   Rosen, Steven D ^c   Uchimura, Kenji ^b,c  

^a ModiQuest BV   (Netherlands)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AICHI MEDICAL UNIVERSITY   (Japan)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Confocal microscopy; Extracellular sulfatase; Flow cytometry; Heparan sulfate; PI 88

Indexed keywords

HEPARAN SULFATE; PI 88; PROTEIN HSULF 1; PROTEIN HSULF 2; SULFATASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EPITOPE; OLIGOSACCHARIDE; PHOSPHOMANNOPENTAOSE SULFATE; RECOMBINANT PROTEIN; SULF1 PROTEIN, HUMAN; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SULFATION; ANIMAL; BIOSYNTHESIS; BRAIN; CHEMISTRY; CRICETULUS; DRUG ANTAGONISM; HAMSTER; METABOLISM; MICROVASCULATURE; MOLECULAR CLONING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRAIN; CELLS, CULTURED; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; EPITOPES; HEPARITIN SULFATE; HUMANS; MICE; MICROVESSELS; OLIGOSACCHARIDES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFOTRANSFERASES;

EID: 77649218826     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp159     Document Type: Article

References (53)

1. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K, Emerson CP Jr. 2006. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem. 281:4969-4976.
2. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP Jr. 2003. QSulf1 remodels the 6-Osulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol. 162:341-351.
3. Ai X, Kitazawa T, Do AT, Kusche-Gullberg M, Labosky PA, Emerson CP Jr. 2007. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development. 134:3327-3338.
4. Ambasta RK, Ai X, Emerson CP Jr. 2007. Quail Sulf1 function requires asparagine-linked glycosylation. J Biol Chem. 282:34492-34499.
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729-777.
6. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans finetune mammalian physiology. Nature. 446:1030-1037.
7. Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A. 2003. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 113:445-456.
8. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem. 280:40066-40073.
9. David G, Bai XM, Van Der Schueren B, Cassiman JJ, Van Den Berghe H. 1992. Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol. 119:961-975.
10. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, van Kuppevelt TH. 2002. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem. 277:10982-10986.
11. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Jr. 2001. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 293:1663-1666.
12. Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K. 2003. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 113:435-444.
13. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest. 108:169-173.
14. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 71:435-471.
15. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA. 82:3197-3201.
16. Freeman SD, Moore WM, Guiral EC, Holme AD, Turnbull JE, Pownall ME. 2008. Extracellular regulation of developmental cell signaling by XtSulf1. Dev Biol. 320:436-445.
17. Frese MA, Milz F, Dick M, Lamanna WC, Dierks T. 2009. Characterization of the human sulfatase sulf1 and its high-affinity heparin/heparan sulfate interaction domain. J Biol Chem. 284:28033-28044.
18. Gallagher JT. 2001. Heparan sulfate: Growth control with a restricted sequence menu. J Clin Invest. 108:357-361.
19. Habuchi H, Habuchi O, Kimata K. 2004. Sulfation pattern in glycosaminoglycan: Does it have a code? Glycoconj J. 21:47-52.
20. Habuchi H, Nagai N, Sugaya N, Atsumi F, Stevens RL, Kimata K. 2007. Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality. J Biol Chem. 282:15578-15588.
21. Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, Carano RA, Frantz GD, Tessier-Lavigne M, Bolon B, et al. 2007. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS ONE. 2:e575.
22. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, et al. 2003. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 162:1151-1162.
23. Ilan N, Elkin M, Vlodavsky I. 2006. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018-2039.
24. Jenniskens GJ, Hafmans T, Veerkamp JH, van Kuppevelt TH. 2002. Spatiotemporal distribution of heparan sulfate epitopes during myogenesis and synaptogenesis: A study in developing mouse intercostal muscle. Dev Dyn. 225:70-79.
25. Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. 2000. Heparan sulfate heterogeneity in skeletal muscle basal lamina: Demonstration by phage display-derived antibodies. J Neurosci. 20:4099-4111.
26. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. 2005. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 24:4037-4051.
27. Khachigian LM, Parish CR. 2004. Phosphomannopentaose sulfate (PI-88): Heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev. 22:1-6.
28. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS. 2002. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res. 62:6312-6317.
29. Kreuger J, Spillmann D, Li JP, Lindahl U. 2006. Interactions between heparan sulfate and proteins: The concept of specificity. J Cell Biol. 174:323-327.
30. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V. 2004. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 23:1439-1447.
31. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, et al. 2008. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 47:1211-1222.
32. Lamanna WC, Baldwin RJ, Padva M, Kalus I, Ten Dam G, van Kuppevelt TH, Gallagher JT, von Figura K, Dierks T, Merry CL. 2006. Heparan sulfate 6-O-endosulfatases: Discrete in vivo activities and functional co-operativity. Biochem J. 400:63-73.
33. Lamanna WC, Frese MA, Balleininger M, Dierks T. 2008. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem. 283:27724-27735.
34. Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Buchler MW, Friess H. 2005. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer. 4:14.
35. Lin X. 2004. Functions of heparan sulfate proteoglycans in cell signaling during development. Development. 131:6009-6021.
36. Lum DH, Tan J, Rosen SD, Werb Z. 2007. Gene trap disruption of the mouse heparan sulfate 6-O-endosulfatase gene, Sulf2. Mol Cell Biol. 27:678-688.
37. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. 2005. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia. 7:1001-1010.
38. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. 2002. Cloning and characterization of two extracellular heparindegrading endosulfatases in mice and humans. J Biol Chem. 277:49175-49185.
39. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, Shridhar V. 2007. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem. 282:14413-14420.
40. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. 2007. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE. 2:e392.
41. Parish CR. 2006. The role of heparan sulphate in inflammation. Nat Rev Immunol. 6:633-643.
42. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. 1999. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59:3433-3441.
43. Powell AK, Yates EA, Fernig DG, Turnbull JE. 2004. Interactions of heparin/ heparan sulfate with proteins: Appraisal of structural factors and experimental approaches. Glycobiology. 14:17R-30R.
44. Saad OM, Ebel H, Uchimura K, Rosen SD, Bertozzi CR, Leary JA. 2005. Compositional profiling of heparin/heparan sulfate using mass spectrometry: Assay for specificity of a novel extracellular human endosulfatase. Glycobiology. 15:818-826.
45. Tang R, Rosen SD. 2009. Functional consequences of the subdomain organization of the sulfs. J Biol Chem. 284:21505-21514.
46. Thery C, Zitvogel L, Amigorena S. 2002. Exosomes: Composition, biogenesis and function. Nat Rev Immunol. 2:569-579.
47. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD. 2006a. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: Effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 7:2.
48. Uchimura K, Morimoto-Tomita M, Rosen SD. 2006b. Measuring the activities of the Sulfs: Two novel heparin/heparan sulfate endosulfatases. Methods Enzymol. 416:243-253.
49. Van Den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M. 2005. Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem. 280:20516-20523.
50. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. 1998. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem. 273:12960-12966.
51. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, Saunders S. 2004. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem. 279:5604-5611.
52. Vlodavsky I, Ilan N, Naggi A, Casu B. 2007. Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 13:2057-2073.
53. Zito E, Fraldi A, Pepe S, Annunziata I, Kobinger G, Di Natale P, Ballabio A, Cosma MP. 2005. Sulphatase activities are regulated by the interaction of sulphatase-modifying factor 1 with SUMF2. EMBO Rep. 6:655-660.